Reaction
Alopecia Areata reporting signals
As of the last recalculation, Alopecia Areata appears in 1,733 FAERS reports alongside 35 co-occurring drug terms. The strongest observed disproportionality signal is BARICITINIB (PRR 62.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Baricitinib | 49 | 62.8 | 63.1 |
| Docetaxel Anhydrous | 290 | 61.9 | 62.1 |
| Docetaxel | 290 | 61.9 | 62.1 |
| Pertuzumab | 50 | 22.7 | 22.8 |
| Trastuzumab | 106 | 19.7 | 19.7 |
| Fosaprepitant Dimeglumine | 22 | 19.4 | 19.5 |
| Prochlorperazine Maleate | 10 | 13.1 | 13.1 |
| Levocetirizine Dihydrochloride | 25 | 12.7 | 12.7 |
| Dexamethasone Sodium Phosphate | 10 | 11.9 | 11.9 |
| Adalimumab-Aaty | 45 | 11.7 | 11.7 |
| Adalimumab-Fkjp | 44 | 11.7 | 11.7 |
| Desloratadine | 10 | 11.3 | 11.3 |
| Adalimumab-Adaz | 48 | 11.2 | 11.2 |
| Aprepitant | 17 | 11.2 | 11.2 |
| Anastrozole Tablets | 18 | 10.2 | 10.2 |
| Mesna Injection | 6 | 8.7 | 8.8 |
| Carboplatin | 87 | 8.6 | 8.6 |
| Mesna | 6 | 8.6 | 8.6 |
| Pegfilgrastim | 67 | 8.4 | 8.4 |
| Clobetasol Propionate Ointment Usp, 0.05% | 7 | 8.2 | 8.2 |
| Clobetasol Propionate | 7 | 8.2 | 8.2 |
| Anastrozole | 23 | 7.6 | 7.6 |
| Ifosfamide | 11 | 6.2 | 6.2 |
| Tofacitinib Citrate | 6 | 5.5 | 5.5 |
| Brivaracetam | 4 | 5.4 | 5.4 |
| Ixekizumab | 13 | 4.2 | 4.2 |
| Minoxidil Foam 5% (Womens) | 11 | 4.0 | 4.0 |
| Minoxidil | 12 | 3.2 | 3.2 |
| Vemurafenib | 3 | 3.0 | 3.0 |
| Drospirenone And Ethinyl Estradiol | 10 | 2.7 | 2.7 |
| Dupilumab | 102 | 2.6 | 2.6 |
| Alirocumab | 5 | 2.4 | 2.4 |
| Levonorgestrel | 39 | 2.4 | 2.4 |
| Guselkumab | 5 | 1.7 | 1.7 |
| Galcanezumab-Gnlm | 4 | 1.5 | 1.5 |